People: Edwards Lifesciences Corp (EW)

EW on New York Consolidated

105.63USD
22 Oct 2014
Price Change (% chg)

$-0.18 (-0.17%)
Prev Close
$105.81
Open
$106.22
Day's High
$106.66
Day's Low
$104.39
Volume
289,389
Avg. Vol
1,001,695
52-wk High
$108.73
52-wk Low
$60.62

Search Stocks

Summary

Name Age Since Current Position

Michael Mussallem

61 2000 Chairman of the Board, Chief Executive Officer

Scott Ullem

47 2014 Chief Financial Officer, Corporate Vice President

Donald Bobo

52 2007 Corporate Vice President - Heart Valve Therapy

Patrick Verguet

56 2004 Corporate Vice President, Europe, Middle East and Africa

Huimin Wang

57 2010 Corporate Vice President, Japan, Asia Pacific

Larry Wood

48 2007 Corporate Vice President - Transcatheter Valve Replacement

Mike Bowlin

71 2012 Independent Director

John Cardis

72 2004 Independent Director

Robert Ingram

71 2003 Independent Director

William Link

67 2009 Independent Director

Barbara McNeil

73 2006 Independent Director

Wesley von Schack

69 2012 Presiding Independent Director

David Erickson

Vice President - Investor Relations

Biographies

Name Description

Michael Mussallem

Mr. Michael A. Mussallem is Chairman of the Board, Chief Executive Officer of Edwards Lifesciences Corp. Prior to 2000, he held a variety of positions with increasing responsibility in engineering, product development, and senior management at Baxter International Inc. ("Baxter"), including Group Vice President of its CardioVascular Group from 1994 to 2000, and Group Vice President of its Biopharmaceutical business from 1998 to 2000. Mr. Mussallem received his Bachelor of Science degree in Chemical Engineering from the Rose-Hulman Institute of Technology and was conferred an honorary Doctorate by his alma mater in 1999. He was a director of Advanced Medical Optics, Inc. from 2002 to 2009, where he chaired the Organization, Compensation and Corporate Governance Committee. Mr. Mussallem currently serves on the boards and executive committees of Advanced Medical Technology Association ("AdvaMed"), California Healthcare Institute, and OCTANe Foundation for Innovation, and is a trustee of the University of California, Irvine Foundation.

Scott Ullem

Mr. Scott B. Ullem has been appointed as Chief Financial Officer, Corporate Vice President of the company., effective January 2, 2014. Ullem joins Edwards from Bemis Company, Inc., where he served as vice president and CFO since 2010. He was previously vice president of finance for the company, which is a major supplier of packaging and pressure sensitive materials used by leading food, consumer products, healthcare and other companies worldwide. Prior to joining Bemis, Ullem held positions of increasing responsibility in the investment banking divisions of both The Goldman Sachs Group, Inc., and Bank of America Corporation. He earned a bachelor's degree from DePauw University and an MBA from Harvard Business School.

Donald Bobo

Mr. Donald E. Bobo, Jr., is Corporate Vice President - Heart Valve Therapy of Edwards Lifesciences Corp. He has also served as Vice President and General Manager of Transcatheter Mitral Repair and as Vice President, Corporate Strategy. Prior to joining the Company in 1995, Mr. Bobo served as Director/General Manager of the Non-Invasive Monitoring Business Unit of InnerSpace, Inc., a medical device startup company. He currently serves as a member of the Board of InnerSpace, Inc. and as a board observer of CardioKinetix, Inc., a healthcare equipment and supply company. Mr. Bobo holds a Bachelor's degree in Mathematics and a Master's degree in Engineering from the University of Southern California.

Patrick Verguet

Mr. Patrick B. Verguet is Corporate Vice President, Europe, Middle East and Africa of Edwards Lifesciences Corp. Since 1984, he served the Company (or Baxter) in various positions including Vice President of Sales, Europe; Global Business Director for hemofiltration; Business Unit/Country Manager for the Company's operations in Western Europe; General Manager of the Company's operations in Utah; and Vice President and General Manager of the Company's Cardiac Surgery Systems business. Mr. Verguet holds a degree as Doctor in Pharmacy from the University of Besançon.

Huimin Wang

Dr. Huimin Wang M.D., is Corporate Vice President, Japan, Asia Pacific of Edwards Lifesciences Corporation. From 2004 to 2010, he served as Corporate Vice President, Japan and Intercontinental and was Corporate Vice President, Japan from 2000 to 2004. Previously, he was a representative director of Baxter Limited, a Japan corporation. Dr. Wang earned his Doctor of Medicine degree from Kagoshima University in Japan and was a Resident and Staff Physician in anesthesiology at Keio University Hospital in Tokyo. He earned his MBA from the University of Chicago. Dr. Wang is a Visiting Associate Professor in the Department of Anesthesiology at Keio University.

Larry Wood

Mr. Larry L. Wood is Corporate Vice President - Transcatheter Valve Replacement of Edwards Lifesciences Corp. From March 2004 to February 2007, he served as Vice President and General Manager, Percutaneous Valve Interventions. From 2001 to 2004, he was the Vice President, Global Franchise Management. Since 1985, Mr. Wood served the Company (or Baxter) in various positions including in manufacturing management and as Senior Director of Regulatory Affairs and Clinical Studies for the Heart Valve Therapy business. Mr. Wood holds a Bachelor's degree in Business and an MBA from Pepperdine University.

Mike Bowlin

Mr. Mike R. Bowlin is Independent Director of Edwards Lifesciences Corp. He served as the Presiding Director until May 2011. He served as Chairman of the Board of Atlantic Richfield Company (which merged with BP Amoco in 2000) from 1995 until his retirement in 2000, as its President from 1993 to 1998, and as its Chief Executive Officer from 1994 to 2000. Mr. Bowlin has been a director of FMC Technologies, Inc. since 2001.

John Cardis

Mr. John T. Cardis is Independent Director of Edwards Lifesciences Corp. Mr. Cardis, a senior partner of Deloitte & Touche until his retirement in 2004, served at Deloitte & Touche for 41 years in positions of increasing responsibility, including as National Managing Partner Global Strategic Clients, as a member of its executive committee for 18 years, and as a member of its board of directors. He has been a director of Avery Dennison Corporation since 2004. Mr. Cardis remains actively involved as a private investor and has served a number of non-profit and community organizations.

Robert Ingram

Mr. Robert A. Ingram is Independent Director of Edwards Lifesciences Corp. He has been a General Partner in the firm Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies, since 2007. Mr. Ingram has served as a strategic advisor to the Chief Executive Officer of GlaxoSmithKline plc, a pharmaceutical research and development company, since January 2010. He previously served as Vice Chairman, Pharmaceuticals, GlaxoSmithKline plc, from 2003 through 2009, and Chief Operating Officer and President of Pharmaceutical Operations, GlaxoSmithKline plc, from January 2001 through January 2003. Mr. Ingram has been on the board of directors of Valeant Pharmaceuticals International since 2003, serving as its Chairman of the Board from 2006 to 2008, when he became its lead director. He was again named Chairman of the Board of Valeant from December 2010 until March 2011, after which he was again appointed Lead Director. Mr. Ingram has also been a director of Cree, Inc., since 2008, serving as its Lead Director since October 2011, and Elan Corporation, since December 2010, serving as its Chairman of the Board since January 2011. Mr. Ingram was a director of Wachovia Corporation until 2008, OSI Pharmaceuticals, Inc., until 2010, Lowe's Companies, Inc., until 2011, Pharmaceutical Product Development Inc., until 2011, and Allergan Inc., until 2012.

William Link

Dr. William J. Link, Ph.D., is Independent Director of Edwards Lifesciences Corp. He is Managing Director and co-founder of Versant Ventures, a venture capital firm investing in early stage healthcare companies. Prior to co-founding Versant Ventures in 1999, Dr. Link was a general partner at Brentwood Venture Capital. From 1986 to 1997, he was founder, Chairman and Chief Executive Officer of Chiron Vision, which was later sold to Bausch & Lomb, Inc. He also founded and served as President of American Medical Optics, Inc., which was acquired by Allergan, Inc. Dr. Link served as a director of Advanced Medical Optics, Inc., from 2002 to 2009. Before entering the healthcare industry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Dr. Link earned his Bachelor's, Master's, and Doctorate degrees in Mechanical Engineering from Purdue University.

Barbara McNeil

Dr. Barbara J. McNeil, M.D., Ph.D., is Independent Director of Edwards Lifesciences Corp. Since 1990, she has served as the Ridley Watts Professor of Health Care Policy at Harvard Medical School. In addition, since 1988, Dr. McNeil has served as the chair of the Department of Health Care Policy at Harvard Medical School. Since 1983, she has been a Professor of Radiology at both Harvard Medical School and Brigham and Women's Hospital. Dr. McNeil served as a director of CV Therapeutics, Inc., from 1994 to 2008. She also served as a director of Flagship Global Health, Inc., from 2005 to 2008. Dr. McNeil is a member of the Institute of Medicine of the National Academy of Sciences (where she was formerly chair of its Board of Healthcare Services) and the American Academy of Arts and Sciences. She is a member and former chair of the Medicare Evidence Development and Advisory Committee and is a member of the Blue Cross Medical Advisory Panel. Dr. McNeil holds an M.D. from Harvard Medical School and a Ph.D. in Biological Chemistry from Harvard University.

Wesley von Schack

Dr. Wesley W. von Schack is Presiding Independent Director of Edwards Lifesciences Corp. He served as Chairman, President, and Chief Executive Officer of Energy East Corporation, an energy services company, from 1996 until his retirement in 2009 (Energy East Corporation was acquired by Iberdrola S.A. in 2008). Mr. von Schack has been a director of the Bank of New York Mellon Corporation since 2007 and is its lead director and chairman of its executive committee. He has been a member of the board of directors of AEGIS Insurance Services since 1997, its chairman since 2006, and a non-executive director of AEGIS Managing Agency Limited, which manages Syndicate 1225 at Lloyd's of London. Mr. von Schack has been a director of Teledyne Technologies, Inc., since 2006. He received his Bachelor's degree in Economics from Fordham University, an MBA from St. John's University, and Doctorate from Pace University.

David Erickson

Basic Compensation

Name Fiscal Year Total

Michael Mussallem

6,611,950

Scott Ullem

--

Donald Bobo

1,930,480

Patrick Verguet

2,483,800

Huimin Wang

--

Larry Wood

1,741,840

Mike Bowlin

--

John Cardis

--

Robert Ingram

--

William Link

--

Barbara McNeil

--

Wesley von Schack

--

David Erickson

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

Michael Mussallem

1,997,397 60,284,450

Scott Ullem

0 0

Donald Bobo

145,330 10,357,000

Patrick Verguet

247,607 9,149,395

Huimin Wang

0 0

Larry Wood

50,800 2,151,510

Mike Bowlin

0 0

John Cardis

0 0

Robert Ingram

0 0

William Link

0 0

Barbara McNeil

0 0

Wesley von Schack

0 0

David Erickson

0 0
Search Stocks